hTERT DNA vaccine - Invectys

Drug Profile

hTERT DNA vaccine - Invectys

Alternative Names: hTERT DNA immunotherapy - Invectys; Human telomerase reverse transcriptase DNA vaccine - Invectys; INVAC-1

Latest Information Update: 15 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Invectys
  • Class Cancer vaccines; DNA vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 31 Aug 2017 Invectys plans a phase II trial for Lymphoid leukaemia (Second-line therapy or greater) (NCT03265717)
  • 02 Jun 2017 Efficacy, pharmacodynamics and adverse events data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
  • 18 Nov 2014 Preclinical trials in Solid tumours in France before November 2014 (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top